ArticleApplied biochemistry and biotechnology2026
An Engineered β-glucosidase from Bacteroides Thetaiotaomicron for Production of Rubusoside from Stevioside.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The consumption of a high-sugar diet has been widely associated with various health complications. Due to its low caloric content, favorable safety profile, and high sweetness, rubusoside has been recognized as a promising alternative to sucrose and synthetic sweeteners. In this study, we report a β-glucosidase from Bacteroides thetaiotaomicron (BtBGL), which specifically hydrolyzes the β-1,2-glucosidic bond in the sophorosyl disaccharide at the C-13 hydroxyl group of stevioside to produce rubusoside. The M98V/Y718F mutant of BtBGL was obtained through consensus design and site-directed mutagenesis. Compared to the wild-type BtBGL, the optimal temperature of the M98V/Y718F mutant increased from 45 °C to 50 °C, demonstrating improved thermostability at this temperature. Additionally, the optimal pH decreased from 6.0 to 5.5, while enzyme activity at pH 5.5 increased from 61.17 U/mg (at pH 6.0) to 83.34 U/mg. This shift in optimal pH remains consistent when stevioside is used as the substrate. The increased surface charge, hydrophobicity, and hydrogen bonding in this double-point mutant may contribute to its enhanced activity at the altered pH and improvement in thermal stability. Stevioside (200 g/L) can be completely converted by the M98V/Y718F mutant within 1 h, and the highest rubusoside yields of 80% and 81% were achieved at 5.5 and 6.0, respectively, after 2 h. This study provides a reference for the engineering of biocatalysts used in rubusoside production.
Indexed as
Identifiers
41920281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.